ECSP10010056A - ANTICUERPOS ANTI-IL-12/23p40, EPÍTOPES, FORMULACIONES, COMPOSICIONES, MÉTODOS Y USOS - Google Patents

ANTICUERPOS ANTI-IL-12/23p40, EPÍTOPES, FORMULACIONES, COMPOSICIONES, MÉTODOS Y USOS

Info

Publication number
ECSP10010056A
ECSP10010056A EC2010010056A ECSP10010056A ECSP10010056A EC SP10010056 A ECSP10010056 A EC SP10010056A EC 2010010056 A EC2010010056 A EC 2010010056A EC SP10010056 A ECSP10010056 A EC SP10010056A EC SP10010056 A ECSP10010056 A EC SP10010056A
Authority
EC
Ecuador
Prior art keywords
methods
compositions
epitopes
formulations
bodies
Prior art date
Application number
EC2010010056A
Other languages
English (en)
Inventor
George A Heavner
David M Knight
Jeffrey Luo
Jill Giles-Komar
David Shealy
David Volkin
Monte Paul Dal
Mehrnaz Khossravi
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of ECSP10010056A publication Critical patent/ECSP10010056A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un anticuerpo anti-IL-12/23p40 que se une a una porción de la proteína IL-12 o IL-23 que corresponde a la subunidad p40 de IL-12 o IL-23, que incluyen composiciones, fórmulas y métodos de administración con aplicaciones en diagnóstico y/o usos y dispositivos terapéuticos.
EC2010010056A 2007-09-28 2010-03-26 ANTICUERPOS ANTI-IL-12/23p40, EPÍTOPES, FORMULACIONES, COMPOSICIONES, MÉTODOS Y USOS ECSP10010056A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97599707P 2007-09-28 2007-09-28

Publications (1)

Publication Number Publication Date
ECSP10010056A true ECSP10010056A (es) 2010-04-30

Family

ID=40850818

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010056A ECSP10010056A (es) 2007-09-28 2010-03-26 ANTICUERPOS ANTI-IL-12/23p40, EPÍTOPES, FORMULACIONES, COMPOSICIONES, MÉTODOS Y USOS

Country Status (9)

Country Link
US (1) US20090181027A1 (es)
EP (1) EP2205276A4 (es)
CR (1) CR11399A (es)
EC (1) ECSP10010056A (es)
GT (1) GT201000073A (es)
HN (1) HN2010000573A (es)
NI (1) NI201000042A (es)
SV (1) SV2010003517A (es)
WO (1) WO2009114040A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201242976A (en) * 2011-01-07 2012-11-01 Abbott Lab Anti-IL-12/IL-23 antibodies and uses thereof
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EP3519049B1 (en) * 2016-09-30 2025-12-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
WO2018181876A1 (ja) 2017-03-31 2018-10-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019106206A1 (en) * 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
WO2019220412A2 (en) 2018-05-18 2019-11-21 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
HUE063462T2 (hu) 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
AU2020320910A1 (en) * 2019-07-30 2022-03-10 Akeso Biopharma, Inc. Anti-human p40 protein domain antibody and use thereof
IL295545A (en) * 2020-02-14 2022-10-01 Janssen Biotech Inc Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN115856281B (zh) * 2022-12-02 2025-06-03 北京世纪沃德生物科技有限公司 基于胶乳免疫比浊法测定il-12的试剂盒及方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
BR0009323A (pt) * 1999-03-25 2002-01-08 Knoll Gmbh Anticorpos humanos que ligam a il-12 humana e métodos para a produção
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US8632778B2 (en) * 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
CA2591813A1 (en) * 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
EP1865986B1 (en) * 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
BRPI0611800A2 (pt) * 2005-06-15 2008-12-09 Schering Corp formulaÇço estÁvel de anticorpo
KR20080025174A (ko) * 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤

Also Published As

Publication number Publication date
CR11399A (es) 2010-08-18
GT201000073A (es) 2012-04-19
HN2010000573A (es) 2012-12-10
EP2205276A4 (en) 2012-08-15
US20090181027A1 (en) 2009-07-16
SV2010003517A (es) 2010-08-10
NI201000042A (es) 2010-09-13
WO2009114040A3 (en) 2010-05-27
EP2205276A2 (en) 2010-07-14
WO2009114040A2 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
CR11399A (es) ANTICUERPOS ANTI-IL-12/23p40, EPITOPES, FORMULACIONES, COMPOSICIONES, METODOS Y USOS
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
MA33023B1 (fr) Formulation d'anticorps
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
EA200870129A1 (ru) Человеческие антитела против il-23, композиции, способы и применение
ECSP077261A (es) Composición de anticuerpo her2
CL2008003537A1 (es) Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor.
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
DK1784426T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
CL2012001853A1 (es) Formulación farmacéutica que comprende un anticuerpo humano que se une de modo especifico al receptor de interleuquina 6 humana (hil-6r), histidina y un carbohidrato.
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201291105A1 (ru) Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
AR051484A1 (es) Moleculas de anticuerpo que tienen especificidad para la il - 17 humana
CR10561A (es) Vacunas para malaria
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
CR10530A (es) Anticuerpos anti-dlla4 y metodos que los usan
TW200745161A (en) Stable antibody formulation
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
AR053026A1 (es) Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso